U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C4H10N2.H3O4P
Molecular Weight 184.1308
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIPERAZINE PHOSPHATE ANHYDROUS

SMILES

OP(O)(O)=O.C1CNCCN1

InChI

InChIKey=NQQWFVUVBGSGQN-UHFFFAOYSA-N
InChI=1S/C4H10N2.H3O4P/c1-2-6-4-3-5-1;1-5(2,3)4/h5-6H,1-4H2;(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula C4H10N2
Molecular Weight 86.1356
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27177234 |

Piperazine, a six membered nitrogen containing heterocycle, is of great significance to the rational design of drugs. This moiety can be found in a plethora of well-known drugs with various therapeutic uses, such as antipsychotic, antihistamine, antianginal, antidepressant, anticancer, antiviral, cardio protectors, anti-inflammatory, and imaging agents. Slight modification to the substitution pattern on the piperazine nucleus facilitates a recognizable difference in the medicinal potential of the resultant molecules. Piperazine has been used as an antihelmintic drug. Piperazine works by paralyzing the worms. They are then passed in the stool.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: UniProtKB: D6BK80_HAECO | D6BJF3_HAECO (GABA receptor subunit)
6.23 mM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MULTIFUGE

Approved Use

Piperazine belongs to the family of medicines called anthelmintics. Anthelmintics are used in the treatment of worm infections. Piperazine is used to treat: common roundworms (ascariasis) and pinworms (enterobiasis; oxyuriasis).

Launch Date

1954
Doses

Doses

DosePopulationAdverse events​
10 mg/m3/h single, respiratory
Studied dose
Dose: 10 mg/m3/h
Route: respiratory
Route: single
Dose: 10 mg/m3/h
Sources:
unhealthy, 42 years
Health Status: unhealthy
Age Group: 42 years
Sex: F
Sources:
Other AEs: Asthma late onset...
Other AEs:
Asthma late onset (1 patient)
Sources:
115 mg/kg 1 times / day steady, oral
Highest studied dose
Dose: 115 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 115 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: F
Sources:
Disc. AE: Myoclonus...
AEs leading to
discontinuation/dose reduction:
Myoclonus (1 patient)
Sources:
65 mg/kg 1 times / day steady, oral
Recommended
Dose: 65 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 65 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
Health Status: unhealthy
Age Group: 9 years
Sex: M
Sources:
Disc. AE: Ataxia...
AEs leading to
discontinuation/dose reduction:
Ataxia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthma late onset 1 patient
10 mg/m3/h single, respiratory
Studied dose
Dose: 10 mg/m3/h
Route: respiratory
Route: single
Dose: 10 mg/m3/h
Sources:
unhealthy, 42 years
Health Status: unhealthy
Age Group: 42 years
Sex: F
Sources:
Myoclonus 1 patient
Disc. AE
115 mg/kg 1 times / day steady, oral
Highest studied dose
Dose: 115 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 115 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: F
Sources:
Ataxia 1 patient
Disc. AE
65 mg/kg 1 times / day steady, oral
Recommended
Dose: 65 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 65 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
Health Status: unhealthy
Age Group: 9 years
Sex: M
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Investigation of synthetic peptide hormones by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry: analysis of a synthesis crude of peptide triptorelin.
2001
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
2001
Synthesis and evaluation of radiolabeled piperazine derivatives of vesamicol as SPECT agents for cholinergic neurons.
2001 Apr
Enzyme immunoassay for 6-amino-5-chloro-1-isopropyl-2-(4-methyl-1-piperazinyl)benzimidazole, a novel 5-HT3 receptor antagonist.
2001 Apr
Acrylamide-based monoliths as robust stationary phases for capillary electrochromatography.
2001 Apr 20
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
2001 Apr 26
A practical GnRH analogue (triptorelin) stimulation test to distinguish constitutional delay of puberty from hypogonadotropic hypogonadism in prepubertal boys.
2001 Apr-Jun
Intracellular PO(2) decreases with increasing stimulation frequency in contracting single Xenopus muscle fibers.
2001 Aug
Diketopiperazine receptors: a novel class of highly selective receptors for binding small peptides.
2001 Aug 3
Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog.
2001 Aug-Sep
Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men.
2001 Dec
Synthesis and stereoselective kappa-receptor binding of methylated analogues of GR-89.696.
2001 Feb
Asymmetric transformation of N-nitrosamines by inclusion crystallization with optically active hosts.
2001 Jan 26
[Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals].
2001 Jan-Mar
Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy.
2001 Jul
Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study.
2001 Jul
Transcarpal motor conduction velocity in carpal tunnel syndrome.
2001 Jul
Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations.
2001 Jul
The use of the indicator fluo-5N to measure sarcoplasmic reticulum calcium in single muscle fibres of the cane toad.
2001 Jul 1
[Study on the latency difference between compound muscle and sensory nerve action potentials].
2001 Jun
Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS.
2001 Jun
Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells.
2001 Jun
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
2001 Jun
Isolation and identification of clozapine metabolites in patient urine.
2001 Jun
Intermolecular and intramolecular Diels-Alder cycloadditions of 3-ylidenepiperazine-2,5-diones and 5-acyloxy-2(1h)-pyrazinones.
2001 Jun 1
Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution.
2001 Jun 13
Determination of the partition coefficients of a homologous series of ciprofloxacin: influence of the N-4 piperazinyl alkylation on the antimicrobial activity.
2001 Jun 4
Investigations of new lead structures for the design of selective estrogen receptor modulators.
2001 Jun 7
Investigation of solid-state reactions using variable temperature X-ray powder diffractrometry. I. Aspartame hemihydrate.
2001 Mar
On the branching of motoneurons.
2001 Mar
Anthelmintic activity of the stem bark extracts of Berlina grandiflora and one of its active principles, Betulinic acid.
2001 Mar
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
2001 Mar 15
[Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa].
2001 May
Requirements for the application of protein sodium dodecyl sulfate-polyacrylamide gel electrophoresis and randomly amplified polymorphic DNA analyses to product speciation.
2001 May
Lumbrical muscle with an additional origin in the forearm.
2001 May
Autoregulation of the gonadotropin-releasing hormone (GnRH) system during puberty: effects of antagonistic versus agonistic GnRH analogs in a female rat model.
2001 May
Fall in intracellular PO(2) at the onset of contractions in Xenopus single skeletal muscle fibers.
2001 May
Direct effects of GnRH agonists in human hormone-sensitive endometrial cells.
2001 May 15
Double-stranded DNA binding characteristics and subcellular distribution of a minor groove binding diphenyl ether bisbenzimidazole.
2001 May 29
Effect of column temperature on the behaviour of some angiotensin converting enzyme inhibitors during high-performance liquid chromatographic analysis.
2001 May 5
Sex hormone replacement therapy reverses decreased venous distensibility in pharmacologically ovariectomized rats.
2001 May-Jun
N1-phenyl substituted 4-quinolones of tuberculostatic activity.
2001 Nov
Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man.
2001 Nov
The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
2001 Nov 19
Synthesis and antibacterial activity of some novel N-substituted piperazinyl-quinolones.
2001 Nov-Dec
Polar nitrogen compounds and their behaviour in the drinking water treatment process.
2001 Oct
Continuous beds with vancomycin as chiral stationary phase for capillary electrochromatography.
2001 Sep
Comparison of practical treatment methods to eradicate pinworm (Dentostomella translucida) infections from Mongolian gerbils (Meroines unguiculatus).
2001 Sep
Use of gonadotropin-releasing hormone analog with tibolone to prevent cyclic attacks of acute intermittent porphyria.
2001 Sep
Kinetics and mechanisms of the reactions of 3-methoxyphenyl, 3-chlorophenyl, and 4-cyanophenyl 4-nitrophenyl thionocarbonates with alicyclic amines.
2001 Sep 7
Patents

Sample Use Guides

No special preparations or other steps (for example, special diet, fasting, other medicines, laxatives, or enemas) are necessary before, during, or immediately after you take piperazine. Piperazine may be taken with or without food or on a full or empty stomach. However, if your doctor tells you to take the medicine a certain way, take it exactly as directed. For patients taking the granules for oral solution form of piperazine: Dissolve the contents of 1 packet of granules in 57 mL (about 2 ounces) of water, milk, or fruit juice. Be sure to drink all of the liquid to get the full dose of medicine. Take this medicine only as directed. Do not take more of it and do not take it more often than your doctor ordered. To do so may increase the chance of serious side effects. To help clear up your infection completely, take this medicine in regularly spaced doses as ordered by your doctor. In some infections, a second treatment with this medicine may be required to clear up the infection completely. Do not miss any doses. For patients taking piperazine for pinworms: Pinworms may be easily passed from one person to another, especially among persons in the same household. Therefore, all household members may have to be treated at the same time to prevent their infection or reinfection. Dosing The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. For granules for oral solution dosage form: For common roundworms or pinworms: Adults and teenagers—2 grams three times a day for one day. Treatment may need to be repeated in two weeks. Children—Dose is based on age and/or body weight. Treatment may need to be repeated in two weeks. Up to 2 years of age: Dose must be determined by your doctor. 2 to 8 years of age: 2 grams once a day for one day. 8 to 14 years of age: 2 grams two times a day for one day. For oral suspension dosage form: For common roundworms or pinworms: Adults and teenagers—1.8 grams every four hours for a total of three doses in one day. Treatment may need to be repeated in two weeks. Children—Dose is based on age. Treatment may need to be repeated in two weeks. Up to 2 years of age: 600 milligrams (mg) every four hours for a total of three doses in one day. 2 to 8 years of age: 1.2 grams every six hours for a total of two doses in one day. 8 to 14 years of age: 1.2 grams every four hours for a total of three doses in one day. For tablet dosage form: For common roundworms: Adults and teenagers—3.5 grams (piperazine hexahydrate) per day for two days in a row. Treatment may need to be repeated in one week. Children—Dose is based on body weight and must be determined by your doctor. However, the usual dose is 75 mg (piperazine hexahydrate) per kilogram (34 mg per pound) of body weight per day for two days in a row. Treatment may need to be repeated in one week. For pinworms: Adults and children—Dose is based on body weight and must be determined by your doctor. However, the usual dose is 65 mg (piperazine hexahydrate) per kilogram (29.5 mg per pound) of body weight per day for seven days in a row. Treatment may need to be repeated in one week. Missed Dose If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:47:25 GMT 2025
Edited
by admin
on Mon Mar 31 20:47:25 GMT 2025
Record UNII
P7S1V82385
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PINROU
Preferred Name English
PIPERAZINE PHOSPHATE ANHYDROUS
Common Name English
PIPERAZATE
Systematic Name English
PIPERVERM
Brand Name English
PIPERAZINE PHOSPHATE [MI]
Common Name English
PIPERAZINE MONOPHOSPHATE
Systematic Name English
PIPERAZINE, PHOSPHATE (1:1)
Systematic Name English
TASNON (TABL.)
Brand Name English
Code System Code Type Description
SMS_ID
100000079475
Created by admin on Mon Mar 31 20:47:25 GMT 2025 , Edited by admin on Mon Mar 31 20:47:25 GMT 2025
PRIMARY
ECHA (EC/EINECS)
238-572-0
Created by admin on Mon Mar 31 20:47:25 GMT 2025 , Edited by admin on Mon Mar 31 20:47:25 GMT 2025
PRIMARY
MERCK INDEX
m8846
Created by admin on Mon Mar 31 20:47:25 GMT 2025 , Edited by admin on Mon Mar 31 20:47:25 GMT 2025
PRIMARY Merck Index
PUBCHEM
64733
Created by admin on Mon Mar 31 20:47:25 GMT 2025 , Edited by admin on Mon Mar 31 20:47:25 GMT 2025
PRIMARY
FDA UNII
P7S1V82385
Created by admin on Mon Mar 31 20:47:25 GMT 2025 , Edited by admin on Mon Mar 31 20:47:25 GMT 2025
PRIMARY
CAS
14538-56-8
Created by admin on Mon Mar 31 20:47:25 GMT 2025 , Edited by admin on Mon Mar 31 20:47:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID70932581
Created by admin on Mon Mar 31 20:47:25 GMT 2025 , Edited by admin on Mon Mar 31 20:47:25 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY